Acromegaly (Western medicine name: gigantism) has been bothering many people. Different from ordinary people's appearance makes many patients feel inferior, and passers-by's different eyes make them unable to lift their heads and dare not face the colorful world directly.

The appearance of the patients is mainly as follows: the expansion of supraorbital ridge, zygoma and mandible results in the exoprocess of eyebrow arch, the protrusion of mandible, the separation of teeth, the dislocation of occlusion, and the protrusion of occipital exoprocess. The scalp is overgrown and drooping with deep folds of gyration, the eyelids are thick, the nose is enlarged and widened, the lips are thick and the tongue is fat, etc.

Acromegaly is an endocrine and metabolic disease, which is caused by the excessive secretion of growth hormone (GH) by adenohypophysis.

The average age of onset was 40-45 years old. Generally, the onset of the disease is slow and the course of disease is long, up to more than 30 years. It is easy to cause a variety of local (headache, visual field defect, brain neuropathy, hydrocephalus and temporal lobe epilepsy), systemic (cardiovascular system, respiratory system, central nervous system, metabolism, tumor, bone) complications.

The common causes of death are cardiovascular and cerebrovascular diseases, dyspnea, diabetes mellitus and colon tumor. The mortality rate is related to the level of GH secreted by adenohypophysis (GH > 10NG / ml).

The treatment of acromegaly can be divided into surgical treatment, radiotherapy and drug treatment. However, neither method is 100% likely to control the disease.

Octreotide acetate injection can control the symptoms of patients with acromegaly who can not be fully controlled by surgery or radiotherapy, and reduce the plasma levels of GH and IGF-1. It can also be used to treat patients with acromegaly who are unable or unwilling to operate, or to treat patients with intermittent acromegaly whose radiotherapy has not yet taken effect.

octreotide acetate injection acetate injection is produced by Chengdu shengnuo biopharmaceutical Co., Ltd. It is a colorless clear liquid, mainly composed of octreotide acetate, supplemented by lactic acid, mannitol, sodium bicarbonate and water for injection.

In addition to acromegaly, it can also be used in the emergency treatment of esophageal variceal bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy), and prevent postoperative complications of pancreas; To alleviate the symptoms and signs related to gastrointestinal and pancreatic endocrine tumors, there is sufficient evidence that this product is effective for the following tumors: Carcinoid with carcinoid syndrome; VIP tumor; glucagon tumor. The effective rate of this product for the following tumors is about 50% (so far, the cases treated with this product are limited): gastrinoma / Zollinger Ellison syndrome, islet tumor, growth hormone releasing factor tumor.

octreotide is a synthetic octreotide compound, which is a 14 peptide human somatostatin analogue. octreotide has similar pharmacological effect with natural hormone, but it has strong inhibitory effect on growth hormone, glucagon and insulin.

Similar to somatostatin, octreotide can also inhibit the response of LH to GnRH, reduce visceral blood flow, and inhibit the secretion of 5-HT, gastrin, vasoactive intestinal peptide, chymotrypsin, motilin and glucagon. No genotoxicity and carcinogenicity were found in the laboratory.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.